David J. Logan
Broad Institute
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by David J. Logan.
American Journal of Pathology | 2010
Anne M. Cataldo; Donna L. McPhie; Nicholas Lange; Steven Punzell; Sarah Elmiligy; Nancy Ye; Michael P. Froimowitz; Linda Hassinger; Emily B. Menesale; Laura W. Sargent; David J. Logan; Anne E. Carpenter; Bruce M. Cohen
Postmortem, genetic, brain imaging, and peripheral cell studies all support decreased mitochondrial activity as a factor in the manifestation of Bipolar Disorder (BD). Because abnormal mitochondrial morphology is often linked to altered energy metabolism, we investigated whether changes in mitochondrial structure were present in brain and peripheral cells of patients with BD. Mitochondria from patients with BD exhibited size and distributional abnormalities compared with psychiatrically-healthy age-matched controls. Specifically, in brain, individual mitochondria profiles had significantly smaller areas, on average, in BD samples (P = 0.03). In peripheral cells, mitochondria in BD samples were concentrated proportionately more within the perinuclear region than in distal processes (P = 0.0008). These mitochondrial changes did not appear to be correlated with exposure to lithium. Also, these abnormalities in brain and peripheral cells were independent of substantial changes in the actin or tubulin cytoskeleton with which mitochondria interact. The observed changes in mitochondrial size and distribution may be linked to energy deficits and, therefore, may have consequences for cell plasticity, resilience, and survival in patients with BD, especially in brain, which has a high-energy requirement. The findings may have implications for diagnosis, if they are specific to BD, and for treatment, if they provide clues as to the underlying pathophysiology of BD.
Nature Chemical Biology | 2013
Kimberly A. Hartwell; Peter Miller; Siddhartha Mukherjee; Alissa R. Kahn; Alison L. Stewart; David J. Logan; Joseph Negri; Mildred Duvet; Marcus Järås; Rishi V. Puram; Vlado Dančík; Fatima Al-Shahrour; Thomas Kindler; Zuzana Tothova; Shrikanta Chattopadhyay; Thomas Hasaka; Rajiv Narayan; Mingji Dai; Christina Huang; Sebastian Shterental; Lisa P. Chu; J. Erika Haydu; Jae Hung Shieh; David P. Steensma; Benito Munoz; Joshua Bittker; Alykhan F. Shamji; Paul A. Clemons; Nicola Tolliday; Anne E. Carpenter
Efforts to develop more effective therapies for acute leukemia may benefit from high-throughput screening systems that reflect the complex physiology of the disease, including leukemia stem cells (LSCs) and supportive interactions with the bone marrow microenvironment. The therapeutic targeting of LSCs is challenging because LSCs are highly similar to normal hematopoietic stem and progenitor cells (HSPCs) and are protected by stromal cells in vivo. We screened 14,718 compounds in a leukemia-stroma co-culture system for inhibition of cobblestone formation, a cellular behavior associated with stem-cell function. Among those compounds that inhibited malignant cells but spared HSPCs was the cholesterol-lowering drug lovastatin. Lovastatin showed anti-LSC activity in vitro and in an in vivo bone marrow transplantation model. Mechanistic studies demonstrated that the effect was on target, via inhibition of HMG-CoA reductase. These results illustrate the power of merging physiologically relevant models with high-throughput screening.
PLOS ONE | 2012
Toshimori Kitami; David J. Logan; Joseph Negri; Thomas Hasaka; Nicola Tolliday; Anne E. Carpenter; Bruce M. Spiegelman; Vamsi K. Mootha
The cellular content of mitochondria changes dynamically during development and in response to external stimuli, but the underlying mechanisms remain obscure. To systematically identify molecular probes and pathways that control mitochondrial abundance, we developed a high-throughput imaging assay that tracks both the per cell mitochondrial content and the cell size in confluent human umbilical vein endothelial cells. We screened 28,786 small molecules and observed that hundreds of small molecules are capable of increasing or decreasing the cellular content of mitochondria in a manner proportionate to cell size, revealing stereotyped control of these parameters. However, only a handful of compounds dissociate this relationship. We focus on one such compound, BRD6897, and demonstrate through secondary assays that it increases the cellular content of mitochondria as evidenced by fluorescence microscopy, mitochondrial protein content, and respiration, even after rigorous correction for cell size, cell volume, or total protein content. BRD6897 increases uncoupled respiration 1.6-fold in two different, non-dividing cell types. Based on electron microscopy, BRD6897 does not alter the percent of cytoplasmic area occupied by mitochondria, but instead, induces a striking increase in the electron density of existing mitochondria. The mechanism is independent of known transcriptional programs and is likely to be related to a blockade in the turnover of mitochondrial proteins. At present the molecular target of BRD6897 remains to be elucidated, but if identified, could reveal an important additional mechanism that governs mitochondrial biogenesis and turnover.
PLOS ONE | 2014
Thomas J.F. Nieland; David J. Logan; Jessica L. Saulnier; Daniel Lam; Caroline A. Johnson; David E. Root; Anne E. Carpenter; Bernardo L. Sabatini
The formation of synapses, the specialized points of chemical communication between neurons, is a highly regulated developmental process fundamental to establishing normal brain circuitry. Perturbations of synapse formation and function causally contribute to human developmental and degenerative neuropsychiatric disorders, such as Alzheimers disease, intellectual disability, and autism spectrum disorders. Many genes controlling synaptogenesis have been identified, but lack of facile experimental systems has made systematic discovery of regulators of synaptogenesis challenging. Thus, we created a high-throughput platform to study excitatory and inhibitory synapse development in primary neuronal cultures and used a lentiviral RNA interference library to identify novel regulators of synapse formation. This methodology is broadly applicable for high-throughput screening of genes and drugs that may rescue or improve synaptic dysfunction associated with cognitive function and neurological disorders.
Journal of Biomolecular Screening | 2010
David J. Logan; Anne E. Carpenter
The typical “design” approach to image-based assay development involves choosing measurements that are likely to correlate with the phenotype of interest, based on the researcher’s intuition and knowledge of image analysis. An alternate “screening” approach is to measure a large number of cellular features and systematically test each feature to identify those that are best able to distinguish positive and negative controls while taking precautions to avoid overfitting the available data. The cell measurement software the authors previously developed, CellProfiler, makes both approaches straightforward, easing the process of assay development. Here, they demonstrate the use of the screening approach to image assay development to select the best measures for scoring publicly available image sets of 2 cytoplasm-to-nucleus translocation assays and 2 Transfluor assays. The authors present the resulting assay quality measures as a baseline for future algorithm comparisons, and all software, methods, and images they present are freely available.
Journal of Biomolecular Screening | 2016
Jing Shan; David J. Logan; David E. Root; Anne E. Carpenter; Sangeeta N. Bhatia
Liver disease is a leading cause of morbidity worldwide and treatment options are limited, with organ transplantation being the only form of definitive management. Cell-based therapies have long held promise as alternatives to whole-organ transplantation but have been hindered by the rapid loss of liver-specific functions over a period of days in cultured hepatocytes. Hypothesis-driven studies have identified a handful of factors that modulate hepatocyte functions in vitro, but our understanding of the mechanisms involved remains incomplete. We thus report here the development of a high-throughput platform to enable systematic interrogation of liver biology in vitro. The platform is currently configured to enable genetic knockdown screens and includes an enzyme-linked immunosorbent assay–based functional assay to quantify albumin output as a surrogate marker for hepatocyte synthetic functions as well as an image-based viability assay that counts hepatocyte nuclei. Using this platform, we identified 12 gene products that may be important for hepatocyte viability and/or liver identity in vitro. These results represent important first steps in the elucidation of mechanisms instrumental to the phenotypic maintenance of hepatocytes in vitro, and we hope that the tools reported here will empower additional studies in various fields of liver research.
Cell Host & Microbe | 2013
Sandra March; Shengyong Ng; Soundarapandian Velmurugan; Ani Galstian; Jing Shan; David J. Logan; Anne E. Carpenter; David Thomas; B. Kim Lee Sim; Maria M. Mota; Stephen L. Hoffman; Sangeeta N. Bhatia
Methods | 2016
David J. Logan; Jing Shan; Sangeeta N. Bhatia; Anne E. Carpenter
Biomaterials | 2017
Frits Hulshof; Bernke J. Papenburg; Aliaksei Vasilevich; Marc Hulsman; Yiping Zhao; Marloes Levers; Natalie Fekete; Meint J. de Boer; Huipin Yuan; Shantanu Singh; Nick R.M. Beijer; Mark-Anthony Bray; David J. Logan; Marcel J. T. Reinders; Anne E. Carpenter; Clemens van Blitterswijk; Dimitrios Stamatialis; Jan de Boer
Experimental Eye Research | 2016
Ana Dordea; Mark-Anthony Bray; Kaitlin Allen; David J. Logan; Fei Fei; Rajeev Malhotra; Meredith S. Gregory; Anne E. Carpenter; Emmanuel Buys